Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
While international guidelines recommend monotherapy with antidepressants for depressed patients, recent investigation has demonstrated augmenting effects of antipsychotics (APs) in patients with major depression. We set out to investigate the use of APs in a European sample of depressed inpatients and the possible changes in their prescription over the period from 2000 to 2007. On two reference days in the years 2000 (32 psychiatric institutions, N=1078) and 2007 (54 psychiatric institutions, N=1826), the following data were recorded for all depressed inpatients (ICD-10: F32.00, F32.01, F32.1, F32.10, F32.11, F32.2, F33.0, F33.00, F33.01, F33.1, F33.10, F33.11, F33.2), monitored as part of the AMSP (Arzneimittelsicherheit in der Psychiatrie) surveillance programme: age, sex, ICD-10 diagnosis and all medication applied on that day. Depressed inpatients with psychotic symptoms were excluded. We found a significant increase in the number of AP-treated inpatients from 37.9% in 2000 to 45.8% in 2007 (χ²=17.257, p<0.001). The number of inpatients who received an atypical AP rose significantly between 2000 and 2007, from 12.8% to 28.3% (χ²=93.37, p<0.001). On the contrary, the percentage of inpatients receiving typical APs showed a significant decrease from 30.2% to 24.1% over the same period (χ²=13.179, p<0.001). Examining only the subgroup of severely depressed inpatients we found an increase in the number of AP-treated inpatients, but this was not statistically significant (χ²=2.047, p=0.15). Our study revealed a significant increase in the usage of atypical APs. However, this effect was not only due to augmentation strategies for severely depressed inpatients. Further studies are needed to examine possible putative effects of AP augmentation treatment in mild to moderate depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
National Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730 · cited 1×
“…are data suggesting the common use of AAPs in depression as a symptomatic treatment, especially for agitation and insomnia (Philip et al. 2008), as well as data showing an increase of AP use in depression in the USA from 1996 to 2005 (Olfson & Marcus, 2009) and 2008–2009 (Lenderts & Kalali, 2009).”
BackgroundNational Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry
Mojtabai, R., & Olfson, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.175 · Cited by 479 · cited 1×
“…sample, the most commonly prescribed AP in 2007 was quetiapine, which has been licensed recently by the FDA for add-on treatment in MDD. Owing to their sedative effect AAPs can be used as sedatives or hypnotics (Hartung et al. 2008) or in order to achieve a quick sedation (Mojtabai & Olfson, 2010).”
BackgroundThase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0207 · Cited by 228
McIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140 · cited 2×
“Thereafter a number of studies investigating the augmentation of antidepressants with APs have been performed in the last decade (e.g. Berman et al. 2007; El-Khalili et al. 2010; Konstantinidis et al. 2007; Künzel et al. 2009; Mahmoud et al. 2007; McIntyre et al. 2007; Thase et al. 2007).”
Background
Cited by
Dold, M., Bartova, L., Souery, D., Mendlewicz, J., Serretti, A., Porcelli, S., Zohar, J., Montgomery, S., & Kasper, S. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.02.020 · Cited by 131
Self-citationSpindelegger, C. J., Papageorgiou, K., Grohmann, R., Engel, R., Greil, W., Konstantinidis, A., Agelink, M. W., Bleich, S., Ruether, E., Toto, S., et al. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu080 · Cited by 82
Self-citationDold, M., Kautzky, A., Bartova, L., Rabl, U., Souery, D., Mendlewicz, J., Porcelli, S., Serretti, A., Zohar, J., Montgomery, S., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.10.005 · Cited by 66
“…with the observations from previous pharmacoepidemiological studies demonstrating a substantial increase of SGA administrations in unipolar depression over the last years (Gerhard et al., 2014; Konstantinidis et al., 2012; Mohamed et al., 2009; Mojtabai and Olfson, 2010, Seemüller et al., 2010).”
InfluentialSelf-citationDold, M., Bartova, L., & Kasper, S. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa034 · Cited by 34
“Accordingly, pharmacoepidemiological surveys consistently revealed a substantial increase of SGA prescriptions in MDD over the last decades (Konstantinidis et al., 2012; Dold et al., 2016; Halfdanarson et al., 2017).”
BackgroundSelf-citation
Metadata
- Authors
- Konstantinidis, A., Papageorgiou, K., Grohmann, R., Horvath, A., Engel, R., & Kasper, S.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-05-17
- Volume
- 15
- Issue
- 04
- Pages
- 449-457
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W1968227463
- Cited by
- 37
- References
- 6
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. https://app.cochat.ai/papers/10.1017/s1461145711000745
- The paper
- Konstantinidis, A., Papageorgiou, K., Grohmann, R., Horvath, A., Engel, R., & Kasper, S. (2012). Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145711000745
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.